source
- Novartis withdraws EU filing for Pluvicto label expansion into early-stage prostate cancerNovartis announced it has pulled its application to the European Medicines Agency to extend the label of its radioligand therapy Pluvicto for use in earlier stages of prostate cancer. The move com…
- Trump announces drug pricing deal with Regeneron, completing White House's 17-deal targetPresident Trump announced a drug‑pricing agreement with Regeneron Pharmaceuticals, marking the final deal in the administration's goal of securing 17 pricing arrangements. The agreement is intende…